BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10824692)

  • 1. The usefulness of serial changes in serum CA19-9 levels in the diagnosis of pancreatic cancer.
    Tanaka N; Okada S; Ueno H; Okusaka T; Ikeda M
    Pancreas; 2000 May; 20(4):378-81. PubMed ID: 10824692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The assessment of serum and diagnostic peritoneal lavage concentration of matrix metalloproteinase-2, matrix metalloproteinase-9, carbohydrate antigen 19-9, and carcinoembryonic antigen in patients with pancreatic cancer and chronic pancreatitis.
    Dranka-Bojarowska D; Lewinski A; Lekstan A; Gajda M; Ciosek J; Mrowiec S
    J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33571962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer.
    Jahan R; Ganguly K; Smith LM; Atri P; Carmicheal J; Sheinin Y; Rachagani S; Natarajan G; Brand RE; Macha MA; Grandgenett PM; Kaur S; Batra SK
    EBioMedicine; 2019 Apr; 42():375-385. PubMed ID: 30956167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels.
    Chang MC; Liang PC; Jan S; Yang CY; Tien YW; Wei SC; Wong JM; Chang YT
    Pancreatology; 2014; 14(5):366-72. PubMed ID: 25278306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis.
    Talar-Wojnarowska R; Gasiorowska A; Olakowski M; Lekstan A; Lampe P; Malecka-Panas E
    Pancreatology; 2010; 10(6):689-94. PubMed ID: 21242708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
    Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
    Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer.
    Zhang J; Wang Y; Zhao T; Li Y; Tian L; Zhao J; Zhang J
    World J Surg Oncol; 2020 Feb; 18(1):31. PubMed ID: 32028958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis.
    Kuwatani M; Kawakami H; Kubota Y; Kawakubo K; Ito YM; Togo S; Ikeda T; Kusama K; Kobayashi Y; Murata T; Sakamoto N
    Pancreatology; 2019 Jun; 19(4):569-577. PubMed ID: 31031206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer.
    Zhao YP; Zhou PT; Ji WP; Wang H; Fang M; Wang MM; Yin YP; Jin G; Gao CF
    Clin Exp Med; 2017 Feb; 17(1):9-18. PubMed ID: 26714469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9.
    Ritchie SA; Chitou B; Zheng Q; Jayasinghe D; Jin W; Mochizuki A; Goodenowe DB
    World J Gastroenterol; 2015 Jun; 21(21):6604-12. PubMed ID: 26074698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The assessment of serum concentration of adiponectin, leptin and serum carbohydrate antigen-19.9 in patients with pancreatic cancer and chronic pancreatitis.
    Dranka-Bojarowska D; Lekstan A; Olakowski M; Jablonska B; Lewinski A; Musialski P; Sobczyk W; Kapalka A; Lampe P
    J Physiol Pharmacol; 2015 Oct; 66(5):653-63. PubMed ID: 26579571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
    Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
    Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer.
    Liu J; Gao J; Du Y; Li Z; Ren Y; Gu J; Wang X; Gong Y; Wang W; Kong X
    Int J Cancer; 2012 Aug; 131(3):683-91. PubMed ID: 21913185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
    Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
    Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis.
    Chang MC; Chang YT; Su TC; Yang WS; Chen CL; Tien YW; Liang PC; Wei SC; Wong JM
    Pancreas; 2007 Jul; 35(1):16-21. PubMed ID: 17575540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis.
    Mroczko B; Groblewska M; Gryko M; Kedra B; Szmitkowski M
    J Clin Lab Anal; 2010; 24(4):256-61. PubMed ID: 20626020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
    Morris-Stiff G; Teli M; Jardine N; Puntis MC
    Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9.
    Forsmark CE; Lambiase L; Vogel SB
    Pancreas; 1994 Nov; 9(6):731-4. PubMed ID: 7846016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.